Drug Alerts
-
Drug Alert 127
doc, 62kb
Falsified batches of Coartem recently circulating in Western and Central Africa -
Drug Alert 126
pdf, 145kb
Contaminated Dextromethorpan Active Pharmaceutical Ingredient -
Drug Alert 125
pdf, 43kb
Contaminated Isotab® (isosorbide mononitrate) incident in Lahore Pakistan -
Drug Alert 124
pdf, 133kb
A/H1N1 vaccination safety: new safety surveillance tool available -
Drug Alert 123
pdf, 50kb
Dextropropoxyphene-containing medicines to be withdrawn from European market -
Drug Alert 122
pdf, 35kb
Warning on purchase of antivirals without a prescription, including via the Internet -
Drug Alert 121
pdf, 147kb
Marketing authorization of efalizumab in the European Union to be suspended due to safety concerns -
Drug Alert 120
pdf, 109kb
Toremifene should not be used in patients at risk of QT-prolongation or other heart problems: recommendation from the European Medicines Agency -
Drug Alert 119
pdf, 67kb
Marketing authorization for rimonabant to be suspended across the European Union since the benefits of the medicine do not outweigh its risks -
Drug Alert 118
pdf, 105kb
Contaminant detected in heparin material of specified origin in the USA and in Germany; serious adverse events reported; recall measures initiated -
Drug Alert 117
pdf, 140kb
Antimalarial chlorproguanil-dapsone (LapDap™) withdrawn following demonstration of post-treatment haemolytic anaemia in G6PD deficient patients in a Phase III trial of chlorproguanil-dapsone-artesunate (Dacart™) versus artemether-lumefantrine (Coartem®) and confirmation of findings in a comparative trial of LapDap™ versus Dacart ™ -
Drug Alert 116
pdf, 104kb
Veralipride (The European Medicines Agency (EMEA) has issued a Press Release recommending the withdrawal of the marketing authorization for all medicinal products containing veralipride). -
Drug Alert 115
pdf, 164kb
Vincristine (chemotherapeutic agent) -
Drug Alert 114
pdf, 67kb
(All batches of Viracept (nelfinavir) recalled from the European Market due to possible contamination with a genotoxic substance) -
Drug Alert 113
pdf, 69kb
(Oral nimesulide: marketing suspended in Ireland due to reports of liver failure) -
Drug Alert 112
pdf, 76kb
(Levaquin {levofloxacin} injection {25 mg/ml 20 ml vials, Batch Nos. 6CB5W00, 6CB6100; Expiry February 2008}: product likely intended for black market use; public health hazard) -
Drug Alert 111
pdf, 63kb
(Cyclooxygenase-2 {COX-2} Inhibitor Medicines) -
Drug Alert 110
pdf, 71kb
{Counterfeit triple antiretroviral combination product (Ginovir 3D) detected in Côte d’Ivoire} -
Drug Alert 109
pdf, 121kb
{Virologic failure in HIV patients treated with the combination of Didanosine, Lamivudine and Tenofovir} -
Drug Alert 108
pdf, 109kb
{Suspension of Manufacturing Licence held by Pan Pharmaceuticals Limited, Sydney} -
Drug Alert 107
pdf, 73kb
{Important safety update on lepirudin (Refludan) following reports of fatal anaphylactic reactions} -
Drug Alert 106
pdf, 74kb
{Risk of serious hypersensitivity and skin reactions with parecoxib sodium The European Medicines Evaluation Agency (EMEA) has issued a public statement} -
Drug Alert 105
pdf, 73kb
{Olanzapine: associations with hyperglycemia resulting in diabetic ketoacidosis and coma} -
Drug Alert 104
pdf, 66kb
{Rapid Alert Notification of a Quality Defect in Prednisolone- Gentamicin (Pred-G) Eye Drops} -
Drug Alert 103
pdf, 77kb
{Nonacog alfa (Benefix) : Intensive post-marketing surveillance and new clinical trials for additional data} -
Drug Alert 102
pdf, 77kb
{Voluntary withdrawal of Cerivastatin – Reports of Rhabdomyolysis} -
Drug Alert 101
pdf, 78kb
{Leflunomide – severe and serious hepatic reactions} -
Drug Alert 100
pdf, 78kb
{Infliximab (Remicade) – reports of tuberculosis infections}